ʻO ka weheʻoleʻana i nā puʻukena maʻi āpau

I ka holomuaʻana o ka maʻi kanesa, hōʻiliʻili lākou i nā haneli haneli a me nā epigenetic, me ka hopena o nā pūnaewele hōʻike pilikino e like me kaʻokoʻa likeʻole o nā pūnaewele olakino. Akā naʻe, me ko lākouʻano palekana nui loa, hiki i nā pūkuniake maʻi ke pale i ka hōʻailona a hōʻehaʻia e ka pūnaewele immune.

ʻO nā Immunotherapies,ʻo nā mea hoʻolālā kelepona e hoʻoulu i nā kolo T a pau, ua hoʻololi i ka mālamaʻana i kekahiʻano o ka maʻi kanesa. ʻO kēia mau hōʻailona hōʻailona ka hopena o ka pane paneʻole no kekahi mau maʻi. ʻO ka mea pōʻino,ʻaʻole hiki i ka hapanui o nā mea maʻi ke pane i nā immunotherapies a me nā kumu hou.

A kime o ka maʻi 'aʻai biologists Including nā lālā o nā keʻena hoʻokolohua o David H. Koch Kumu o ka kālaimeaola Tyler Jack, ka luna hoʻokele o ka Koch Institute no Integrative Cancer Research ma mit a me kekahi mau hoa lâlâ Koch Institute Forest White, ka Ned a me Janet C. Bemis Kumu Rice a me ka hoa o ka mit Center no Cancer Medicine miomio, Lawe ae la lakou i ka mea manuahi e hoʻokokoke i boosting i ka'ōnaehana paleʻea nenoaiu.

ʻOiai ua pili pinepineʻia nā pūkuniaʻau me nā protein mutant, eʻikeʻia kēia mau protein ma kahi o kahi kelepona, kahi eʻikeʻia ai e nā pūnaewele kūlohelohe. Ua hoʻihoʻi hou ka poʻe noiʻi i kahi lālā hoʻonaʻauao o nā lāʻau lapaʻau anti-cancer, nā mea hoʻopiʻi kūoho hoʻolālāʻo 90 (HSP90), a he mea hiki ke hoʻomaopopoʻia ma nā hōʻikeʻana i ka pilikino e hoʻomalu.

Ua hoʻonui nuiʻia nā mea hoʻonāukiuki HSP90 no nā maʻamau maʻi maʻi. Hast i ka HSP90 i ka hoʻoikaika i ka hoʻolālāʻenehana i hoʻopiliʻia e nā hoʻololi likeʻole. Eia nō naʻe, me ka hōʻike pūʻana i nā'ōlelo hōʻike mua, hoʻolaha ka HSP90 i nā hopena hōʻoluʻolu i nā hoʻokolohua hoʻokolohua, aʻaʻohe mea i loaʻa ka FDA.

i ka like ʻikeʻia Ke Kelepona Lapaʻau KinoUa hōʻike nā mea noiʻi i kahi kumu kumu o kēlā mau hopena hopena. Ua hoʻokolohua ponoʻia ka HSP90 mea hōʻailona ma keʻano o ka pulus dos - ka lōʻihiʻole, a me nā kau nui -ʻo ka hopena i loaʻa i nā hopena i makemakeʻoleʻia i nā maʻi.

RNA profiling o kanaka lapaʻau Eia kekahi laʻana a me ka hana 'ike loea Ka maʻi' aʻai aeea laina e hōʻike ana e keia-bolus dosing haʻalele 'ana i nā hualoaʻa ma ka walaau ole suppression o ka'ōnaehana paleʻea haʻawina like hoʻi me ka ho'ā hope o ka wela kŰia ololi kumuʻiʻo 1 (HSF1). 'Aʻole wale nō' aʻole HSF1 haʻalele i ka halepaahao i ka wela kŰia pane, qui counteracts i ka hopena o ka inhibitor HSP90, AIM ka mea, ua ikeia e ia i ka ikaika loa enabler o ka maʻi 'aʻai aeea malignancy.

I luku Akä naÿe, i ka Cancer noiʻi hoʻohana iole Ke Ana Hoʻohālike me kōna'ōnaehana paleʻea nenoai, e hōʻike i malama aku, haʻahaʻa-ʻilikai dosing o nā mea kūpale HSP90 hookaaokoa ae mai o Ua triggering i ka wela nń pane a me ka immunosuppression pili me ka kiʻekiʻe nā māhele.

Hoʻohana 'ana i kekahi hana noʻonoʻoʻia e ka White Keʻena E hui nuipa a spectrometry-Aʻo proteomics a me computational hōʻikeʻia nani, ka noiʻi loaa hou dosing regimen que la ia, a mahuahua nui i ka helu a me ka nohona o nā peptides (kumuʻiʻo hakina) ma luna o ka halepaahao ili honua. Mau peptides, qui loaʻa i ke kime e e hoʻokuʻuʻia HSP90 I malama aku haʻahaʻa-ʻilikai inhibition He Alaila, noa ia e lawe mai ma ka halepaahao ka antigen-ka hōʻike hana a me ka hoʻohana 'ana i ka hae Patrolling'ōnaehana paleʻea keena.

"Kēia mau hualoaʻa hoʻohui he kumu, ao ke ano o ka ke kelepona hele kālaimeaola - kumuʻiʻo pelu - i Anati-ʻeho'ōnaehana paleʻea pane" wahi a ke alakaʻi i kekahi mea kākau Alex Jaeger, he postdoctoral kanaka i loko o ka Jack keʻene hoʻokolohua, a me ka palapala lâlâ o ke keʻena hoʻokolohua o ka weuweu mit biologist a me Kumu Susan Lindquist , kona hana, ho'āla aʻela i ke ao ka dosing HSP90 scheule. "Hopefully, mākou mau mea, ua ulu ke reinvigorate hoihoi i loko o HSP90 inhibition like me ka mea manuahi hoʻokokoke no immunotherapy."

E ho ohana i ka hou dosing regimen, ka noiʻi He loea ae hoomaemae loa oia hikoko ma ka iole Ke Ana Hoʻohālike ma ka lāʻau nā hoʻohui like mea i 25-50 manawa haʻahaʻa ma mua o ka poe i hoʻohana i ka lapaʻau hoao ana, ālai 'hoemi i ka'Ākena no kaʻawahiaʻaoʻao' ole i loko o nā mea maʻi. Importantly, No kekahi mau ano o HSP90 nā mea kūpale-Ua Undergone ano nui lapaʻau ikea ai, me ka hou dosing regimen hiki ke ikea i loko o nā mea maʻi koke.

Ua kākoʻoʻia kēia hana e ke Damon Runyon Cancer Research Foundation, ka Kāmika'Āina'okapaʻiʻo Takeda, a me ka MIT Training Grant i kaʻike'enekema; ua kākoʻoʻia kahi hana ma HSF1 e ke Koch Institute Frontier Research Program.

Uaʻike muaʻia kēiaʻatikala http://news.mit.edu/2019/unmasking-mutant-cancer-cells-0717